Assessing the Efficacy of Dextran and Dextransucrase in Modulating MCF-7 Breast Cancer Cell Activity
DOI:
https://doi.org/10.36320/ajb/v15.i3.13211Keywords:
angiogenesis, cytotoxic, IC50, Neoplasms and viabilityAbstract
Abstract
Tumor development is a complex process involving abnormal cell proliferation within an organism. This study aims to understand tumors, their categorization, formation methods, and effects on human health. Tumor growth is influenced by genetic, environmental, and lifestyle factors. Dextran, a glucose-based polysaccharide, has been used in medical applications for blood plasma substitutes and antithrombotic agents. Researchers are interested in its potential therapeutic applications due to its biocompatibility and unique properties. Dextransucrase, a glucosyltransferase, plays a vital role in synthesizing glucan polymers. Advancements in cancer research reveal the nuanced roles of biopolymers like dextran in tumor biology, drug delivery, and cancer therapy.
In this study MCF-7 cell line maintained in MEM, reseeded twice a week, incubated at 37°C. The MTT cell viability assay was conducted on 96-well plates to assess cytotoxic effects. Cell lines were seeded, treated with the tested compound, and measured after 72 hours. After solubilization, absorbency was determined using a microplate reader at 492 nm.
The results showed A decrease in cell viability was observed with decreasing Dextran concentration, with a negative correlation between concentration and cell viability. A P-value of 0.001 indicates statistically significant effects on MCF-7 cell cytotoxicity, rejecting the null hypothesis that Dextran has no effect. Dextransucrase exhibited a dose-dependent cytotoxicity effect on MCF-7 cells, with a significant effect at the highest concentration (1000) and a negative correlation at the lowest concentration (31.25). The P-value of 0.001 was below the 0.05 threshold, rejecting the null hypothesis. According to the results of cell viability, the highest concentration (1000) had the lowest viability, while the lowest concentration (31.25) had the highest. The data supports the cytotoxic potential of Dextransucrase in a dose-dependent manner.
Downloads
References
R. Baghban, L. Roshangar, R. Jahanban-Esfahlan, K. Seidi, A. Ebrahimi-Kalan, M. Jaymand, S. Kolahian, T. Javaheri, P. Zare, Cell Communication and Signaling 2020 18:1 18 (2020) 1–19. DOI: 10.1186/S12964-020-0530-4
J. Fares, M.Y. Fares, H.H. Khachfe, H.A. Salhab, Y. Fares, Signal Transduct Target Ther 5 (2020). DOI: 10.1038/S41392-020-0134-X
A. Maitra, Nature 567 (2019) 181–182. DOI: 10.1038/D41586-019-00710-Z
H. Zhao, L. Wu, G. Yan, Y. Chen, M. Zhou, Y. Wu, Y. Li, Signal Transduction and Targeted Therapy 2021 6:1 6 (2021) 1–46. DOI: 10.1038/s41392-021-00658-5
J. Massagué, A.C. Obenauf, Nature 529 (2016) 298–306. DOI: 10.1038/NATURE17038
A.R. Petrovici, M. Pinteala, N. Simionescu, Molecules 28 (2023). DOI: 10.3390/MOLECULES28031086
Z. Xie, W. Liang, Q. Xiong, Y. Zhao, J. Cheng, X. Li, J. Zhao, Carbohydr Polym 291 (2022). DOI: 10.1016/J.CARBPOL.2022.119576
by A. Nathan Jones, M.M. Banaszak Holl Steven Bloembergen, G.H. Biomedical Professor Emeritus Brian Clarkson Professor Jinsang Kim, (n.d.).
M.M. Vantangoli, S.J. Madnick, S.M. Huse, P. Weston, K. Boekelheide, PLoS One 10 (2015). DOI: 10.1371/JOURNAL.PONE.0135426
N. Bajalovic, Y.Z. Or, A.R.E. Woo, S.H. Lee, V.C.L. Lin, Biomedicines 10 (2022). DOI: 10.3390/BIOMEDICINES10081860/S1
N.T. Telang, International Journal of Molecular Sciences 2022, Vol. 23, Page 4800 23 (2022) 4800. DOI: 10.3390/IJMS23094800
D.J. Konieczkowski, C.M. Johannessen, L.A. Garraway, Cancer Cell 33 (2018) 801–815. DOI: 10.1016/J.CCELL.2018.03.025
M. Szostakowska, A. Trębińska-Stryjewska, E.A. Grzybowska, A. Fabisiewicz, Breast Cancer Res Treat 173 (2019) 489–497. DOI: 10.1007/S10549-018-5023-4
F. Ghaffari, M. Bahmanzadeh, A. Nili-Ahmadabadi, F. Firozian, Asian Pac J Cancer Prev 19 (2018) 2651–2655. DOI: 10.22034/APJCP.2018.19.9.2651
J. Varshosaz, F. Hassanzadeh, H. Sadeghi, F. Firozian, M. Mirian, J Nanomater 2012 (2012). DOI: 10.1155/2012/265657
K. Joyce, G.T. Fabra, Y. Bozkurt, A. Pandit, Signal Transduction and Targeted Therapy 2021 6:1 6 (2021) 1–28. DOI: 10.1038/s41392-021-00512-8
T. Hillman, Front Oncol 13 (2023) 1194350. DOI: 10.3389/FONC.2023.1194350/BIBTEX
E. Lukášová, M. Řezáčová, A. Bačíková, L. Šebejová, J. Vávrová, S. Kozubek, FEBS Open Bio 9 (2019) 870. DOI: 10.1002/2211-5463.12632
P. Ferraboschi, S. Ciceri, P. Grisenti, Antibiotics 10 (2021). DOI: 10.3390/ANTIBIOTICS10121534
M.S. Khan, B.H.J. Gowda, N. Nasir, S. Wahab, M.R. Pichika, A. Sahebkar, P. Kesharwani, Int J Pharm 643 (2023) 123276. DOI: 10.1016/J.IJPHARM.2023.123276
J. Ma, D.J. Waxman, Mol Cancer Ther 7 (2008) 3670. DOI: 10.1158/1535-7163.MCT-08-0715
N. Barzkar, O. Babich, R. Das, S. Sukhikh, S. Tamadoni Jahromi, M. Sohail, Molecules 27 (2022). DOI: 10.3390/MOLECULES27175533
Downloads
Published
Versions
- 2024-01-07 (6)
- 2024-01-07 (5)
- 2024-01-07 (4)
- 2024-01-07 (3)
- 2024-01-07 (2)
- 2023-12-31 (1)
How to Cite
Issue
Section
License
Copyright (c) 2023 Yasameen Hasan Ali, 2 Sahira Nsayef, 3 Israa Hussein Hamzah
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
